Alpha Cognition Inc. (ACOGF)
USD 5.73
(0.0%)
USD 5.73
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.22 Million USD | 0.74% |
| 2022 | 1.21 Million USD | 12.61% |
| 2021 | 1.07 Million USD | -66.54% |
| 2020 | 3.21 Million USD | 276.0% |
| 2019 | 855.06 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.21 Million USD | -0.29% |
| 2024 Q1 | 1.21 Million USD | -0.44% |
| 2023 Q4 | 1.22 Million USD | 5.5% |
| 2023 FY | 1.22 Million USD | 0.74% |
| 2023 Q3 | 1.15 Million USD | 1.44% |
| 2023 Q2 | 1.14 Million USD | -2.3% |
| 2023 Q1 | 1.16 Million USD | -3.66% |
| 2022 Q4 | 1.21 Million USD | 3.06% |
| 2022 FY | 1.21 Million USD | 12.61% |
| 2022 Q2 | 1.14 Million USD | 3.0% |
| 2022 Q1 | 1.1 Million USD | 2.95% |
| 2022 Q3 | 1.17 Million USD | 3.05% |
| 2021 Q3 | 1.04 Million USD | 2.98% |
| 2021 Q2 | 1.01 Million USD | 2.93% |
| 2021 Q1 | 985.46 Thousand USD | -2.84% |
| 2021 Q4 | 1.07 Million USD | 3.0% |
| 2021 FY | 1.07 Million USD | -66.54% |
| 2020 Q3 | 985.46 Thousand USD | 0.0% |
| 2020 FY | 3.21 Million USD | 276.0% |
| 2020 Q4 | 1.01 Million CAD | 2.93% |
| 2019 Q4 | 855.06 Thousand USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 855.06 Thousand USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 97.038% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 70.393% |
| SQZ Biotechnologies Company | 27.47 Million USD | 95.558% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 97.186% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 95.9% |
| Mesoblast Limited | 118.7 Million USD | 98.972% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -28.694% |
| Genus plc | 233.1 Million USD | 99.476% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | 58.355% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 9.17% |
| Marizyme, Inc. | 18.71 Million USD | 93.48% |
| ContraFect Corporation | 2.88 Million USD | 57.641% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -62.716% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -800.73% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | 15.622% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | 47.532% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 78.432% |
| MultiCell Technologies, Inc. | 202.58 USD | -602314.848% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 97.877% |
| EV Biologics, Inc. | 1.49 Million USD | 18.356% |
| Q BioMed Inc. | 4.1 Million USD | 70.307% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 96.313% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -93.686% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | 0.65% |
| Biomind Labs Inc. | 735.54 Thousand USD | -65.915% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 99.289% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 90.61% |
| Skye Bioscience, Inc. | 4.61 Million USD | 73.558% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -37.419% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -762.344% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 79.214% |
| IMV Inc. | 28.88 Million USD | 95.775% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -4645.021% |
| Curative Biotechnology, Inc. | 2.25 Million USD | 45.963% |
| GB Sciences, Inc. | 1.75 Million USD | 30.633% |
| HST Global, Inc. | 98.31 Thousand USD | -1141.237% |
| CSL Limited | 12.18 Billion USD | 99.99% |
| Halberd Corporation | 150 Thousand USD | -713.581% |
| Enzolytics Inc. | 996.33 Thousand USD | -22.486% |
| Resverlogix Corp. | 6.49 Million USD | 81.199% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -155.575% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -377.469% |
| argenx SE | 20 Million USD | 93.898% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 97.321% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 54.946% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -11835.178% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.708% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -508.312% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | 49.103% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -432.237% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 98.196% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | 59.673% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -239.266% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 93.997% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -720.948% |
| BioStem Technologies, Inc. | 4.71 Million USD | 74.098% |
| ONE Bio Corp. | 19.71 Million USD | 93.81% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -387.794% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -390.661% |
| Agentix Corp. | 50 Thousand USD | -2340.744% |
| LadRx Corporation | 33.6 Thousand USD | -3531.411% |
| Cell Source, Inc. | 9.25 Million USD | 86.813% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -61.381% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -61.381% |
| NovAccess Global Inc. | 2.19 Million USD | 44.526% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 82.746% |
| Itoco Inc. | 228.37 Thousand USD | -434.367% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -478.444% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 75.509% |
| Kadimastem Ltd | 891.22 Thousand USD | -36.932% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -203.689% |
| CytoDyn Inc. | 30.07 Million USD | 95.942% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -151.995% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -246.847% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 84.394% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -896.222% |
| Rebus Holdings, Inc. | 310 Thousand USD | -293.668% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 74.228% |
| International Stem Cell Corporation | 4.17 Million USD | 70.791% |
| Bioxytran, Inc. | 1.92 Million USD | 36.604% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1855.317% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 44.043% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 85.325% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 85.785% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | 21.544% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -355.363% |
| Neutra Corp. | 54.15 Thousand USD | -2153.438% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | 33.313% |
| PureTech Health plc | 25.51 Million USD | 95.216% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | 0.315% |
| IXICO plc | 472.02 Thousand USD | -158.541% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 92.127% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 98.04% |
| CSL Limited | 12.18 Billion USD | 99.99% |
| Cellectis S.A. | 92.77 Million USD | 98.685% |